↓ Skip to main content

Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study

Overview of attention for article published in Trials, May 2005
Altmetric Badge

Mentioned by

1 Wikipedia page


72 Dimensions

Readers on

39 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study
Published in
Trials, May 2005
DOI 10.1186/1468-6708-6-9
Pubmed ID

Bengt Fellström, Faiez Zannad, Roland Schmieder, Hallvard Holdaas, Alan Jardine, Helen Rose, Wim Wilpshaar, the AURORA Study Group


Patients with end-stage renal disease (ESRD) are at high risk of cardiovascular events. Multiple risk factors for atherosclerosis are present in ESRD and may contribute to the increased risk of cardiovascular mortality in this population. In contrast to patients with normal renal function, the benefits of modifying lipid levels on cardiovascular outcomes in patients with ESRD on haemodialysis have yet to be confirmed in large prospective randomised trials. A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events (AURORA) will be the first large-scale international trial to assess the effects of statin therapy on cardiovascular morbidity and mortality in ESRD patients on chronic haemodialysis.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 39 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 10%
Researcher 4 10%
Student > Postgraduate 4 10%
Professor 3 8%
Student > Bachelor 3 8%
Other 10 26%
Unknown 11 28%
Readers by discipline Count As %
Medicine and Dentistry 17 44%
Business, Management and Accounting 2 5%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Biochemistry, Genetics and Molecular Biology 1 3%
Nursing and Health Professions 1 3%
Other 4 10%
Unknown 12 31%